Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IFRX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Vilobelimab | Pyoderma Gangrenosum | Phase 3 · NCT05964413 | Terminated |
| BSC Mouse | Severe COVID-19 Pneumonia | Phase 2/3 · NCT04333420 | Completed |
| HS high dose treatment | Chronic Urticaria, Idiopathic | Phase 2 · NCT06555328 | Terminated |
| HS medium dose treatment | Chronic Urticaria, Idiopathic | Phase 2 · NCT06555328 | Terminated |
| Glucocorticoid | Granulomatosis With Polyangiitis (GPA) | Phase 2 · NCT03895801 | Completed |
| CSU non responders IgE - high dose treatment | Chronic Urticaria, Idiopathic | Phase 2 · NCT06555328 | Terminated |
| CSU lower dose treatment | Chronic Urticaria, Idiopathic | Phase 2 · NCT06555328 | Terminated |
| CSU high dose treatment | Chronic Urticaria, Idiopathic | Phase 2 · NCT06555328 | Terminated |
| Cohort C: bevacizumab | Acute Respiratory Distress Syndrome (ARDS) | Phase 2 · NCT06701656 | Recruiting |
| Cohort B: paridiprubart | Acute Respiratory Distress Syndrome (ARDS) | Phase 2 · NCT06701669 | Recruiting |
| Cohort A: vilobelimab | Acute Respiratory Distress Syndrome (ARDS) | Phase 2 · NCT06703073 | Recruiting |
| CaCP29, a humanized monoclonal antibody | Drug Safety | Phase 1 · NCT01319903 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IFRX holds $115.4M in cash and short-term investments and burns about $4.7M/quarter from operations, an estimated runway of 74.1 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 22 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IFRX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Montanova Capital, LLC | Institution (13G, 5%+) | 22,933,910 | 31.72% | 2026-06-30 |
| TCG Crossover GP III, LLC | 5%+ holder (13G) | 14,500,000 | 20.06% | 2026-05-07 |
| Commodore Capital LP | Institution (13G, 5%+) | 9,268,220 | 12.82% | 2026-09-30 |
| Sirenia Capital Management LP | Institution (13G, 5%+) | 8,911,348 | 12.33% | 2026-06-30 |
| FMR LLC | Institution (13G, 5%+) | 8,163,341 | 11.29% | 2026-06-30 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | Institution (13G, 5%+) | 7,933,910 | 10.97% | 2025-12-31 |
| Dapice Joshua J. | 5%+ holder (13G) | 7,500,000 | 10.37% | 2026-05-07 |
| Renfeng Guo Chief Scientific Officer, Director |
Insider | 1,762,144 | 2.44% | 2026-03-18 |
| Niels Riedemann Chief Executive Officer, Director |
Insider | 1,068,908 | 1.48% | 2026-03-18 |
| Mark Kubler Director |
Insider | 960,015 | 1.33% | 2026-03-18 |
| Nicolas Fulpius Director |
Insider | 490,052 | 0.68% | 2026-03-18 |
| Richard Brudnick Director |
Insider | 50,000 | 0.07% | 2026-03-18 |
Share count 72,292,859 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IFRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →